Unravelling Cancer's Blueprint
A New Era of Targeted Therapy – Precision oncology advancing first-in-class therapeutics for patients with high-risk cancers.
Pioneering Precision Oncology
We are dedicated to developing next-generation cancer therapeutics by targeting cancer's core vulnerabilities.
Born from Urgency
At Coiled, we're building a new paradigm for precision medicine. Our journey began with the conviction that the next wave of therapeutic breakthroughs lies in precisely targeting historically intractable proteins, particularly coiled-coil and other structurally complex oncogenic targets.
Spun out from A2A Pharmaceuticals, Inc. in 2025, Coiled is a focused, clinical-stage oncology company advancing promising new therapies for cancer. Following the reverse takeover of Roquefort Therapeutics, we are now listed on the London Stock Exchange AIM market and cross-traded on the OTCQB Venture Market in the United States.
Learn more about us